Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1800 participants.

Also called NCT06736574

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,800 participants (planned count) (from the registry)
Sponsor
  • Cytokinetics Registry lists this organization as the lead sponsor
Registry
  • NCT NCT06736574
  • EU CT 2024-519219-32-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Canada, China, France, Germany, Greece, Italy, Poland, Spain, United Kingdom (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06736574. Randomized; quadruple masking; primary purpose treatment. Start 2024-12-19 (actual); primary completion 2027-09 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
Acronym
COMET-HF
Condition
Heart Failure
Intervention (Drug)
Omecamtiv Mecarbil (OM)
Intervention (Drug)
Placebo
Lead sponsor
Cytokinetics (class: industry)

Record details

Record id
cardio:ct-nct06736574
Content hash
1e6587e3d0161071fdfa0fdfffb2be6ced215a706719595b46619335429e9e67